HEMAMALINI MADHUKAR | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Dr. HEMAMALINI MADHUKAR | Cancer Cell Biology | Best Researcher Award

Dr. HEMAMALINI MADHUKAR, Mother Teresa Women’s University, India

Dr. Madhukar Hemamalini is an accomplished Assistant Professor in the Department of Chemistry at Mother Teresa Women’s University, Kodaikanal. With over five and a half years of dedicated research experience and eight years of teaching, she has made significant contributions to the field of structural and bioorganic chemistry. Her expertise lies in X-ray crystallography, protein-ligand interactions, and the synthesis of supramolecular and pharmaceutical compounds. She earned her Ph.D. in Chemistry from Bharathidasan University and completed a postdoctoral fellowship under Prof. H.-K. Fun at Universiti Sains Malaysia. With 234 international publications and a citation index reflecting her research impact, Dr. Hemamalini’s academic presence is both global and influential. Her guidance to 10 M.Phil. and 21 M.Sc. students reflects her commitment to mentoring the next generation of scientists. She actively contributes to academic committees and has led a UGC Minor Research Project on hydrogen bonding and phase transition.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Extensive Publication Record

    • Over 234 international research publications, primarily in reputed journals such as Journal of Molecular Structure, Molecular Diversity, Russian Journal of Inorganic Chemistry, and IUCrData.

    • Research themes include X-ray crystallography, drug-likeness prediction, molecular docking, and biochemical analysis.

  2. Strong Research Background

    • Postdoctoral research in crystallography at Universiti Sains Malaysia (USM) under a globally respected crystallographer, Prof. H.-K. Fun.

    • More than five and a half years of focused research experience in supramolecular and macromolecular chemistry.

  3. Citation Impact

    • Accumulated 228 citations, with a h-index of 12 and i10-index of 8, reflecting a solid impact in her field.

  4. Mentorship & Teaching

    • 8 years of teaching experience as an Assistant Professor.

    • Mentored 10 M.Phil. and 21 M.Sc. students — demonstrating her commitment to research training and knowledge dissemination.

  5. Research Funding

    • Successfully secured UGC Minor Research Project funding of ₹5,00,000 for studies on hydrogen bonding and phase transition.

  6. Academic Service

    • Contributed to institutional growth as inspection committee member for women’s colleges, affirming leadership in academic governance.

⚠️ Areas for Improvement:

  1. Enhance International Collaboration

    • Collaborations beyond Malaysia, particularly with Europe or North America, could increase citation visibility and interdisciplinary reach.

  2. Diversify Funding Sources

    • Apply for major national/international grants (e.g., DST, DBT, SERB, or industry-academic partnerships) for scaling research infrastructure and student involvement.

  3. Intellectual Property & Innovation

    • Translating research into patents, prototypes, or industry consultancies would enhance her research’s practical value and real-world impact.

  4. Public Engagement and Outreach

    • Participation in conferences as keynote speaker, science communication, or popular science articles would further establish her academic persona.

🎓 Education:

Dr. Madhukar Hemamalini completed her Ph.D. in Chemistry in October 2006 from Bharathidasan University, India, specializing in structural and supramolecular chemistry. Her doctoral research focused on the synthesis and crystallographic analysis of organic compounds, laying a strong foundation for her future work in macromolecular systems. Prior to her doctorate, she obtained her M.Sc. in Chemistry in August 2000 and B.Sc. in Chemistry in August 1998, both from Bharathidasan University. Her academic training has equipped her with a deep understanding of chemical interactions at the molecular level, especially those relevant to drug design, protein-ligand binding, and pharmaceutical solids. Her academic trajectory showcases her longstanding passion for exploring the molecular world through advanced techniques like X-ray crystallography and computational chemistry. Additionally, her exposure to interdisciplinary research at Universiti Sains Malaysia has expanded her global outlook and enriched her research methodologies.

🧪 Experience:

Dr. Hemamalini has a cumulative 13+ years of experience in academia and research. She is currently serving as Assistant Professor at the Department of Chemistry, Mother Teresa Women’s University, Kodaikanal since March 2015. Her teaching portfolio includes mentoring postgraduate and M.Phil. students, with 21 M.Sc. and 10 M.Phil. students successfully guided under her supervision. From December 2009 to February 2012, she pursued Post-Doctoral research in X-ray crystallography at Universiti Sains Malaysia under the mentorship of Prof. H.-K. Fun, focusing on supramolecular motifs and metal coordination complexes. Her total research experience spans over five and a half years, during which she explored protein-ligand interactions, crystal engineering, and bioorganic compound synthesis. She also participated in institutional academic committees and inspection boards, contributing to higher education quality assurance. Her dual expertise in both teaching and high-impact research makes her a well-rounded academic professional.

🏆 Awards and Honors:

Dr. Madhukar Hemamalini has been the recipient of the prestigious Senior Research Fellowship (SRF) from the Council of Scientific and Industrial Research (CSIR), New Delhi (2004–2006), which stands as a testimony to her research potential and academic rigor. In addition to this major national honor, she has been involved in several university-level academic panels, including Inspection Committees for women’s colleges in Dindigul, highlighting her contributions to academic governance and quality control. Her funded project under the UGC Minor Research Project Scheme—with a sanctioned amount of ₹5,00,000—focused on the hydrogen bonding interactions and phase transition studies in organic compounds, an area of current interest in molecular chemistry. Her work has been cited over 228 times, and she holds a h-index of 12 and an i10-index of 8, reflecting a consistent and meaningful research output across international journals.

🔬 Research Focus:

Dr. Hemamalini’s research revolves around X-ray crystallography, macromolecular chemistry, and supramolecular design. Her scientific interest lies in unraveling structure–function relationships in molecules, particularly in protein-ligand complexes, bioorganic frameworks, and pharmaceutical solids. She has applied her expertise in both experimental (e.g., crystal growth and structural analysis) and computational techniques (e.g., molecular docking, dynamics simulations) to synthesize novel compounds with potential drug-like behavior. Her interdisciplinary approach bridges chemistry with biology, enabling her to work on problems like TNF-α inhibition in rheumatoid arthritis, anti-cancer screening, and antidiabetic compound design. She has actively published in reputed journals, showcasing both synthetic and theoretical studies. Her postdoctoral training at Universiti Sains Malaysia helped her master crystallographic techniques, further enriching her analytical capabilities. Her work continues to contribute valuable insights into biomolecular recognition, drug-receptor modeling, and material science.

📚 Publications Top Notes: 

  1. 📄 Synthesis of 3-Methoxy…phenol Schiff base: spectral, in-silico & in-vitro studies – Heliyon, 2022

  2. 🧬 In silico and in vitro identification of TNF-α inhibitors from Euphorbia hirta for rheumatoid arthritis – Molecular Diversity, 2025

  3. 💊 Anti-diabetic activity of pyrimidinium-hydrogen oxalate conjugates: synthesis, docking & simulation – Journal of Molecular Structure, 2025

  4. 🧪 [2-(1H-indol-3-yl)ethyl]-(4-nitrobenzylidene)amine: anti-breast cancer & antibacterial insights – Journal of Molecular Structure, 2025

  5. 🔬 PPI networking, expression analysis & TNF-α inhibitor screening for RA – Molecular Diversity, 2025

  6. 🧫 6-Bromo-9,9-diethyl-N,N-diphenylfluoren-2-amine – Data Paper

  7. 🧊 Insights into oxidovanadium porphyrin: synthesis & Hirshfeld surface analysis – Journal of Molecular Structure, 2024

  8. 🧬 1,4-Dimethylpiperazine-2,3-dione – crystal structure study – Iucrdata, 2024

  9. ⚗️ (1H-Benzodiazol-2-ylmethyl)diethylamine – molecular characterization – Iucrdata, 2024

  10. 🔍 Structural & oxidative studies of (3,4,5-trimethoxyphenyl)Porphyrin Ni(II) Complex – Russian Journal of Inorganic Chemistry, 2024

🧾 Conclusion:

Dr. Madhukar Hemamalini possesses a well-rounded academic profile with consistent research output, teaching excellence, mentorship, and academic service. Her work in structural and medicinal chemistry, particularly involving crystallography and biomolecular interactions, has practical implications in drug discovery and material science. She demonstrates all the key markers of a successful and impactful researcher.

Rong Zhong | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Prof. Rong Zhong | Cancer Cell Biology | Best Researcher Award

Prof. Rong Zhong, Huazhong University of Science and Technology, China

Professor Rong Zhong is an esteemed academic in the field of molecular and cancer epidemiology at Tongji Medical College, Huazhong University of Science and Technology, China. With a PhD in Epidemiology and Biostatistics and postdoctoral training from Harvard Medical School, she has built a distinguished career in investigating genetic and environmental interactions in cancer development. Over the years, she has led 51 research projects, authored 169 peer-reviewed articles, and earned over 3,600 citations. Dr. Zhong’s collaborative work extends across national and international institutions, including Huazhong Agricultural University and the General Hospital of Central Theater Command. Recognized with the Natural Science Award of Hubei Province, she is also actively involved in several national scientific committees. Her commitment to advancing cancer prevention through precision medicine and early detection strategies reflects both her scientific acumen and societal impact, making her a strong candidate for the Best Researcher Award.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Extensive Research Output

    • 169 SCI/Scopus-indexed publications, many in high-impact journals like Gastroenterology, Nature Reviews Clinical Oncology, and Cancer Discovery.

    • Strong citation record with 3,697 citations on Web of Science, reflecting broad scientific influence.

  2. Innovative and Impactful Research

    • Focus on molecular and cancer epidemiology, particularly gene-environment interactions in gastrointestinal cancers, addressing a critical public health challenge.

    • Groundbreaking research on environmental risk factors (e.g., bisphenol A, tobacco smoke) and genetic susceptibility in cancer risk.

  3. Grants and Funding Leadership

    • Principal investigator of major national research projects, including National Natural Science Foundation of China grants and the Young Top-notch Talent Cultivation Program of Hubei Province.

  4. Recognition and Service

    • Recipient of the Natural Science Award of Hubei Province.

    • Serves on editorial boards of reputable journals such as Ebiomedicine and American Journal of Gastroenterology.

    • Active member in national scientific committees related to cancer prevention and epidemiology.

  5. Collaboration and Mentorship

    • Strong institutional and cross-disciplinary collaborations, including with Huazhong Agricultural University and military medical research institutions.

    • A demonstrated leader in mentoring young researchers in public health and biomedical science.

⚙️ Areas for Improvement:

  1. Industry Engagement & Technology Transfer

    • Although she holds 2 patents, there is limited mention of industry consultancy or commercialization, which could strengthen real-world impact.

  2. International Policy Influence

    • Expanding her involvement in international advisory boards or global health policy initiatives could further elevate her research visibility and societal contribution.

  3. Science Communication & Public Engagement

    • Enhanced participation in public education, community outreach, or policy translation could help bridge science and society, especially in preventive oncology.

🎓 Education:

Dr. Rong Zhong earned her PhD in Epidemiology and Biostatistics from the prestigious Huazhong University of Science and Technology, where she built the foundation for her future research excellence. To further expand her academic perspective, she completed postdoctoral training at Harvard Medical School, USA—an experience that enriched her global outlook and enhanced her methodological rigor in public health research. Throughout her academic journey, Dr. Zhong has demonstrated a passion for understanding complex interactions between genes and environmental exposures, particularly in relation to cancer epidemiology. Her education, characterized by a blend of rigorous Chinese academic training and Western research exposure, has laid a strong interdisciplinary base. This robust academic background has equipped her with a unique skill set to lead impactful research in molecular epidemiology and precision prevention of gastrointestinal cancers.

💼 Experience:

Dr. Rong Zhong currently serves as a Professor at the School of Public Health, Tongji Medical College, Huazhong University of Science and Technology. With extensive experience in cancer epidemiology, she has successfully led national and provincial research initiatives including projects funded by the National Natural Science Foundation of China and the Young Top-notch Talent Cultivation Program of Hubei Province. Over the years, she has been instrumental in mentoring young scientists, shaping national health policies, and advancing cancer prevention strategies in China. She also serves on editorial boards of high-impact journals such as Ebiomedicine and American Journal of Gastroenterology. Her experience bridges research, academic leadership, and international collaboration, reflecting her multidimensional contribution to science and public health. Her advisory roles in national committees focused on cancer prevention and epidemiology further underscore her influence and thought leadership in the field.

🔬 Research Focus:

Professor Zhong’s primary research focus lies in molecular and cancer epidemiology, with an emphasis on gastrointestinal cancers. Her work aims to elucidate the gene-environment interactions that contribute to cancer risk, leveraging large-scale cohort and case-control studies. By integrating genomic data with environmental exposures (e.g., diet, pollutants, endocrine-disrupting chemicals), she develops predictive models that enable early screening and personalized prevention strategies for high-risk populations. Her recent studies investigate interactions between genetic polymorphisms and substances like bisphenol A, tobacco smoke, and gut microbiota, especially in relation to colorectal and breast cancer. These contributions bridge the gap between basic science and clinical translation, offering a pathway toward precision public health. Her research not only advances scientific knowledge but also holds tangible implications for national cancer screening guidelines and individualized preventive healthcare strategies.

📚 Publications Top Notes:

  1. 📘 Western-Style Diet, pks Island-Carrying Escherichia coli, and Colorectal Cancer: Analyses From Two Large Prospective Cohort Studies – Gastroenterology

  2. 🚬 In Utero and Childhood/Adolescence Exposure to Tobacco Smoke, Genetic Risk and Lung Cancer Incidence and Mortality in Adulthood – AJRCCM

  3. 🧬 FOXA1 of regulatory variant associated with risk of breast cancer through allele-specific enhancer in the Chinese population – Breast Cancer

  4. 🧪 Genome-wide gene-bisphenol A, F and triclosan interaction analyses on urinary oxidative stress markers – Science of The Total Environment

  5. 🧫 Urinary bisphenol A and its interaction with CYP17A1 rs743572 are associated with breast cancer risk – Chemosphere

  6. 🧠 Animal-eRNAdb: a comprehensive animal enhancer RNA database – Nucleic Acids Research

  7. 🔬 Hepatocellular carcinoma risk variant modulates lncRNA HLA-DQB1-AS1 expression via a long-range enhancer–promoter interaction – Carcinogenesis

  8. 🧍‍♀️ Bisphenol A exposure, interaction with genetic variants and colorectal cancer via mediating oxidative stress biomarkers – Environmental Pollution

  9. 🧾 Discovery and Features of an Alkylating Signature in Colorectal Cancer – Cancer Discovery

  10. 🚨 Rising incidence of early-onset colorectal cancer — a call to action – Nature Reviews Clinical Oncology

📌 Conclusion:

Professor Rong Zhong is an outstanding and highly qualified candidate for the Best Researcher Award. Her prolific output, innovative approaches to cancer risk assessment, and leadership in national scientific research firmly position her among the top-tier researchers in her field. Her contributions have laid the groundwork for precision public health, with real potential to transform early cancer detection and prevention strategies in China and globally.

Junfeng Zhang | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Assoc. Prof. Dr. Junfeng Zhang | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Junfeng Zhang, Anhui University of Science and Technology, China

Dr. Junfeng Zhang is an Associate Professor and Deputy Director of the Center for Medical Frontiers at the School of Medicine, Anhui University of Science and Technology. With a Ph.D. in biomedical sciences, he has emerged as a leading figure in nanomedicine and cancer theranostics. His work integrates nanotechnology, molecular imaging, and drug delivery systems, particularly focusing on intelligent nanoformulations for tumor targeting and integrated diagnostics and therapy. Dr. Zhang is an active member of multiple national medical committees and has contributed significantly to interdisciplinary research. His publications in prestigious journals like Advanced Materials, Small Methods, and Advanced Science reflect both scientific depth and translational potential. As a council and committee member of several medical and health associations, he actively promotes collaboration across academic and healthcare institutions. His dedication to innovation and public health positions him as a rising star in biomedical engineering and personalized cancer therapy.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. High-Impact Research Contributions

    • Dr. Zhang has published in top-tier international journals such as Advanced Materials (IF: 32.086), Advanced Science (IF: 15.1), and Small Methods (IF: 15.367).

    • His work demonstrates interdisciplinary excellence—combining nanotechnology, oncology, and imaging science to address complex medical challenges.

  2. Innovative Scientific Focus

    • Focused on intelligent theranostic nanoformulations, his research targets both diagnostic imaging and cancer therapy in a single platform.

    • He has developed laser-free imaging systems, nucleus-targeted drug delivery platforms, and responsive nanosystems, which are highly relevant to personalized and precision medicine.

  3. Leadership & Recognition

    • Serves as the Deputy Director of the Center for Medical Frontiers, showing strategic leadership.

    • Holds multiple national-level committee memberships, indicating peer recognition and influence in the field of nuclear medicine, digital health, and environmental mutagen studies.

  4. Collaborative & Global Research Impact

    • Frequently collaborates with international researchers like Prof. Rui L. Reis.

    • Demonstrates versatility in both experimental and translational research, addressing real-world medical and toxicological issues.

  5. Consistent Productivity

    • Maintains a consistent and strong publication record as first/corresponding author over the past five years, with multi-disciplinary themes.

⚠️ Areas for Improvement:

  1. Commercialization & Patent Activity

    • While his work is scientifically advanced, there is limited visible emphasis on patent filings, technology transfer, or startup ventures. Increasing focus here would enhance his profile for innovation-based awards.

  2. International Outreach

    • Although involved in collaborations, more visibility in international scientific conferences, editorial boards, or global awards could further strengthen his candidacy on the world stage.

  3. Public Health Engagement

    • As his work is deeply relevant to cancer management, more visible contributions to community awareness, patient education, or policy advisory roles could broaden the societal impact of his research.

🎓 Education:

Dr. Junfeng Zhang earned his doctoral degree (Ph.D.) in biomedical sciences, with a specialization in nanomedicine and molecular diagnostics. While the specific university name is not listed, the rigorous research output suggests training from a high-caliber institution. His education integrated core principles of pharmacology, biomedical engineering, and cancer biology, allowing him to build a strong foundation in interdisciplinary medical research. During his academic career, he focused on translational research that merges engineering, imaging technologies, and clinical applications. Through his doctoral training, Dr. Zhang acquired advanced techniques in nanoparticle synthesis, fluorescence imaging, and drug delivery. His education paved the way for impactful research in photoacoustic imaging and intelligent targeted therapies. Dr. Zhang’s academic background equipped him to lead cutting-edge research projects that align with global challenges in oncology. He continues to leverage his academic foundation to mentor graduate students and drive innovation in healthcare technology development.

🧪 Experience:

Dr. Zhang currently serves as Associate Professor and Deputy Director of the Center for Medical Frontiers at the School of Medicine, Anhui University of Science and Technology. He holds prominent roles including Council Member of the Anhui Provincial Society of Environmental Mutagens and committee memberships in nuclear medicine and digital health bodies. With over five years of experience in biomedical research and teaching, he has led numerous research projects at the interface of nanomedicine, cancer biology, and imaging diagnostics. His international collaborations and editorial contributions signify global recognition. As a mentor, he guides students and young researchers in clinical translation of nano-based therapies. His leadership at the Center for Medical Frontiers emphasizes high-impact innovation, collaborative research culture, and practical solutions to oncological diseases. His diverse experience in academic, clinical, and committee roles demonstrates his comprehensive influence in shaping future medical technologies and public health strategies.

🔬 Research Focus:

Dr. Zhang’s research focuses on the development of intelligent theranostic nanoformulations aimed at achieving both diagnosis and treatment of tumors in a single platform. His work emphasizes dual-mode imaging systems (photoacoustic/fluorescence), targeted drug delivery, and biocompatible nanocarriers capable of bypassing biological barriers. One of his key innovations involves creating gold- and carbon-based nanomaterials for laser-free imaging and mitochondrial apoptosis induction. He is particularly interested in nucleus-targeted therapies, precision drug delivery, and responsive nanosystems that adjust to tumor microenvironments. He also studies the toxicological aspects of nanomedicines under various physiological conditions, including magnetic field exposure and metabolic pathway disruptions. His research bridges disciplines like pharmacology, materials science, and medical imaging, contributing to the personalized medicine movement. With a strong publication record in high-impact journals, his research focus reflects a commitment to translating laboratory innovations into clinical applications to improve cancer diagnosis, treatment precision, and therapeutic outcomes.

📚 Publications Top Notes:

  1. 🧬 A Multifunctional Photoacoustic/Fluorescence Dual-Mode-Imaging Gold-Based Theranostic Nanoformulation without External Laser Limitations – Advanced Materials, 2022

  2. 💊 An Efficient Carbon-Based Drug Delivery System for Cancer Therapy through the Nucleus Targeting and Mitochondria Mediated Apoptotic Pathway – Small Methods, 2021

  3. 🧠 Humanistic Health Management and Cancer: Associations of Psychology, Nutrition, and Exercise with Cancer Progression and Pathogenesis – Advanced Science, 2024

  4. 🌿 Preparation, Characterization, and Evaluation of the Antitumor Effect of Kaempferol Nanosuspensions – Drug Delivery and Translational Research, 2023

  5. 🐟 High Concentrations of Fluorescent Nanoprobes Delayed Oryzias Melastigma Embryo Hatching by Modulating Respiratory and Metabolic Pathways – VIEW, 2025

  6. 🧲 The Biokinetics and Toxicology of Fe₃O₄ Nanoparticles Influenced by Magnetic Field and Protein – Nano, 2022

🧾 Conclusion:

Dr. Junfeng Zhang is a highly suitable and deserving candidate for the Best Researcher Award. His cutting-edge work in nanomedicine, combined with consistent high-impact publications, academic leadership, and contributions to national scientific bodies, clearly mark him as a rising and influential scientist in the medical research community. With slight enhancements in technology translation and international public engagement, he holds potential to become a global leader in biomedical innovation.

Yanlan Wang | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Dr. Yanlan Wang | Cancer Cell Biology | Best Researcher Award

Dr. Yanlan Wang, Stanford, United States

Dr. Yanlan Wang is a distinguished postdoctoral research fellow at Stanford University’s Department of Pathology. She works in the esteemed Dr. Gerald Crabtree’s lab, where her research revolves around leveraging molecular glues to reprogram cancer drivers and trigger apoptosis. With a strong background in immuno-oncology, antibody engineering, and small molecule therapeutics, Dr. Wang has made significant contributions to targeted cancer therapies. Her interdisciplinary collaborations, notably with Dr. Nathanael Gray’s group, have explored the role of transcription factor complex-inducing compounds (TCIPs) in MLL-rearranged leukemia. Dr. Wang brings a rich international research experience from China and the U.S., with a career spanning translational medicine, biotechnology innovation, and academic excellence. She is known for her rigorous approach to scientific inquiry, collaborative spirit, and prolific publication record. Her passion for understanding and overcoming the mechanisms of cancer resistance positions her as a future leader in oncology drug development and precision medicine.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Outstanding Research Focus
    Dr. Wang’s work on molecular glues and transcription factor modulators represents cutting-edge approaches in cancer therapy, especially in targeting previously undruggable pathways.

  2. High Impact Publications
    With multiple first-author and co-corresponding author papers (e.g., J Immunol Methods 2025, Leukemia & Lymphoma 2020, Clin Pharmacol Ther 2021), Dr. Wang has demonstrated a strong track record in both fundamental and translational cancer research.

  3. Innovation & Translational Impact
    Her efforts in bispecific antibody engineering, IL-15 therapeutics, and AKR1C3-targeted prodrugs show clear applications in oncology drug development, bridging the lab and clinic.

  4. Prestigious Collaborations
    Collaborating with renowned researchers such as Dr. Gerald Crabtree and Dr. Nathanael Gray at Stanford indicates high confidence and integration in world-class research circles.

  5. Recognition & Awards
    She has received the Coxe Fellowship at Stanford and multiple merit-based scholarships, highlighting academic excellence and innovation.

  6. Leadership and Multidisciplinary Skills
    Dr. Wang has led several projects, authored high-level papers, and mentored junior researchers, showcasing both technical and leadership capability.

🔄 Areas for Improvement:

  1. Greater International Presentation Exposure
    Although she has strong publication credentials, more visibility through international oral presentations, keynote addresses, or panel roles would amplify her leadership profile.

  2. Independent Grant Record
    While she is currently in a postdoctoral role, seeking independent funding (e.g., K99/R00, early-career PI grants) would position her more competitively for independent investigator status.

  3. Patent or Commercial Translation
    Given the translational nature of her work, pursuit of intellectual property filings or biotech partnerships would further highlight impact.

🎓 Education:

Dr. Yanlan Wang began her academic journey at Xiangya School of Medicine, Central South University, where she earned her MBBS (M.D. equivalent) in June 2012. She continued at The Second Xiangya Hospital for her clinical residency, completing her M.S. in June 2015. Her pursuit of scientific excellence led her to earn a doctorate (M.D. equivalent to PhD) from Sun Yat-sen University in June 2018, with a research focus on microbial immunology and tumor biology. This diverse educational background gave her a solid foundation in both clinical medicine and biomedical research, allowing her to bridge translational gaps in cancer research. Her early training emphasized immunotherapy, molecular biology, and oncology, all of which paved the way for her postdoctoral work in cutting-edge labs. Her education reflects a consistent upward trajectory, marked by prestigious institutions, interdisciplinary training, and a seamless integration of clinical and scientific disciplines.

🔬 Experience:

Dr. Yanlan Wang is currently a postdoctoral research fellow in Dr. Gerald Crabtree’s lab at Stanford University, where she focuses on manipulating cancer cell pathways using molecular glues. Her prior research in China included pivotal roles in biotechnology innovation, including bispecific antibody engineering, prodrug design, and immune-oncology drug development. She has also collaborated extensively with Dr. Nathanael Gray’s lab at Stanford, exploring the therapeutic potential of TCIPs in leukemia. Dr. Wang’s hands-on experience includes multiplex screening platforms, flow cytometry, in vivo tumor models, and translational immunotherapy development. Over the years, she has taken leadership roles in preclinical projects, manuscript authorship, and international scientific presentations. Her diverse roles—from clinical residency to laboratory innovation—reflect her capability to translate complex scientific findings into therapeutic strategies. Dr. Wang has also mentored junior researchers and worked across multiple disciplines, underscoring her adaptability, leadership potential, and deep commitment to cancer research.

🏅 Awards and Honors:

Dr. Yanlan Wang’s excellence has been recognized through several prestigious awards. At Stanford, she received the Coxe Fellowship in 2021, honoring outstanding postdoctoral researchers. During her doctoral training, she earned the Special Award of Merit for the BJ-001 Project at BJ Bioscience Inc. in 2019 for her impactful translational research. Her academic merit was consistently acknowledged through the Bidi Scholarship (2016–2017) and Daxiang Scholarship (2015–2016) at Sun Yat-sen University. These honors underscore her commitment to scientific excellence, innovation, and translational impact in oncology and immunotherapy. Her ability to receive awards across both academic and industrial settings highlights her versatility and the real-world relevance of her work. These distinctions serve as a testament to her leadership in cancer drug development, collaborative effectiveness, and contribution to next-generation therapeutic discoveries.

🔍 Research Focus:

Dr. Yanlan Wang’s research lies at the intersection of cancer biology, molecular pharmacology, and immunotherapy. At Stanford, she investigates how molecular glues can be used to hijack cancer drivers and activate apoptosis, offering a novel route for targeted cancer therapies. Her work involves multiplex molecular glue screening, understanding protein degradation pathways, and designing synthetic lethality strategies. In collaboration with Dr. Nathanael Gray, she is also studying Transcription factor Complex-Inducing Compounds (TCIPs) for the treatment of MLL-rearranged leukemia, a particularly aggressive form of blood cancer. Prior to this, her research focused on bispecific antibodies, prodrugs, and IL-15 based immunotherapeutics, with a vision to decouple efficacy from toxicity. Through a blend of basic science and translational applications, she aims to rewire oncogenic signaling pathways and enhance anti-tumor immunity. Her research combines drug discovery, systems biology, and precision oncology, pushing the boundaries of targeted cancer treatment.

📚 Publications Top Notes:

  1. 🔬 Quantitative flow cytometry using quantitative streptavidin-protein G-biotin beads (qBeads) – J Immunol Methods, 2025

  2. 🧬 A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-directed Cell Death – Cell (revising)

  3. 💉 Enhance IL15 anti-tumor efficacy by inhibiting its negative feedback mechanism – (in preparation)

  4. ⚛️ Decouple the toxicity and efficacy of BJ-001, an integrin targeting IL-15 – AACR Abstract, 2019

  5. 🔄 Decoupling the toxicity and efficacy of immunotherapeutics – SITC Abstract, 2019

  6. 🧪 An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL – Leukemia & Lymphoma, 2020

  7. 🧫 A novel AKR1C3 specific prodrug TH3424 with potent anti-tumor activity in liver cancer – Clin Pharmacol Ther, 2021

  8. 🧲 A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity – J Vis Exp, 2018

  9. 🧠 Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies – Cancer Biol Ther, 2020

  10. 🧿 Bp-Bs, a novel T-cell engaging bispecific antibody with biparatopic Her2 binding – Mol Ther Oncolytics, 2019

  11. 🧰 A novel multi-functional anti-CEA-IL15 molecule displays potent anti-tumor activities – Drug Des Devel Ther, 2018

  12. 🧠 A single domain based anti-Her2 antibody has potent anti-tumor activities – Transl Oncol, 2018

🧾 Conclusion:

Dr. Yanlan Wang is highly deserving of the Best Researcher Award. Her contributions to cancer therapeutics through novel molecular approaches, her collaborations with globally renowned labs, and her publication record reflect a researcher of exceptional caliber and promise. With a deep understanding of tumor biology, a commitment to innovation, and a growing leadership presence in oncology research, she is not only suitable for the award but stands as a strong role model for future biomedical researchers.

Hyung Joon Kim | Oral cancer | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr. Hyung Joon Kim | Oral cancer | Best Researcher Award

Prof. Dr. Hyung Joon Kim, Pusan National University School of Dentistry, South Korea

Dr. Hyung Joon Kim is a distinguished Professor at the Department of Oral Physiology, School of Dentistry, Pusan National University. With a robust foundation in molecular biology and dental sciences, Dr. Kim has made significant contributions to the understanding of bone biology, particularly in the contexts of periodontitis, osteoclast/osteoblast function, and bone metastasis. His research bridges fundamental science and clinical application, focusing on regenerative therapies using dental cells. Over the years, he has held key research and academic positions at Seoul National University and Kyung Hee University, where he advanced investigations into bone metabolism and periodontal regeneration. An accomplished academic, Dr. Kim has published extensively in high-impact journals, exploring complex signaling pathways and therapeutic targets in bone-related diseases. His work stands out for its interdisciplinary approach and translational potential, positioning him as a strong candidate for the Best Researcher Award in biomedical sciences.

Publication Profile: 

Scopus

Orcid

✅ Strengths for the Award:

  1. Strong Academic Background
    Dr. Kim holds a BS in Molecular Biology and a PhD in Dentistry from two of South Korea’s top institutions, establishing a multidisciplinary foundation in both basic science and clinical research.

  2. Focused and Impactful Research
    His research areas—osteoclast/osteoblast biology, bone metastasis, dental stem cell therapy, and periodontitis—address critical global health issues. His work bridges fundamental science and therapeutic applications, enhancing its clinical relevance.

  3. Impressive Publication Record
    With multiple peer-reviewed papers in internationally recognized journals like J Bone Miner Res, Int J Mol Sci, and Cells, Dr. Kim has demonstrated consistent and high-quality scientific output.

  4. Leadership and Experience
    He has held senior and professorial positions at leading research centers and universities for over a decade, highlighting his expertise, leadership, and mentorship skills.

  5. Interdisciplinary Approach
    His integration of molecular biology, regenerative dentistry, and systemic disease pathways reflects innovation and cross-disciplinary thinking—key for future-focused research.

🔧 Areas for Improvement:

  1. Global Collaboration & Outreach
    While Dr. Kim has a strong national profile, increasing international collaborations, joint publications, or involvement in global research consortia could further elevate his influence and recognition.

  2. Translational and Clinical Application
    More emphasis on clinical trials or patent filings based on his lab’s findings would help translate laboratory success into real-world impact, strengthening his candidacy for awards focused on innovation.

  3. Funding and Grants Visibility
    Public visibility of high-impact grants or funding awards received would reinforce the trust and investment the research community places in his work.

🎓 Education:

Dr. Hyung Joon Kim began his academic journey at Pusan National University, where he earned his Bachelor of Science in Molecular Biology (1996–2004). Building on this strong foundation in biological sciences, he pursued advanced research in dental sciences, obtaining a Ph.D. from the Department of Dentistry at Seoul National University (2004–2009). His doctoral work integrated molecular biology with dental pathophysiology, setting the stage for his later specialization in bone metabolism and regenerative medicine. His multidisciplinary educational background enabled him to explore complex biological processes with a clinical perspective, particularly in understanding the mechanisms of osteoclast and osteoblast regulation, and their roles in periodontitis and systemic disease. The combination of molecular insight and clinical relevance in his education forms the cornerstone of his innovative research, equipping him to contribute meaningfully to the academic and clinical dental community.

💼 Professional Experience:

Dr. Kim’s professional career spans over 15 years of dedicated research and teaching. He began as a Senior Researcher (2009–2013) at the Bone Metabolism Research Center, Seoul National University, where he led projects on osteoclast function and bone pathology. He then served as a Research Professor (2013–2014) at the Tooth and Periodontal Tissue Regeneration Center, Kyung Hee University, further deepening his expertise in dental tissue engineering. Since 2014, Dr. Kim has been serving as an Associate Professor (now Professor) at the School of Dentistry, Pusan National University, where he leads multiple research initiatives and mentors future dental researchers. His career reflects a consistent focus on translational bone biology, contributing not only to scientific advancement but also to academic excellence. His blend of research innovation and educational leadership makes him an impactful figure in oral physiology and regenerative medicine.

🔬 Research Focus:

Dr. Hyung Joon Kim’s research is centered on understanding the cellular and molecular mechanisms of bone regeneration and destruction, particularly through the lens of osteoclast and osteoblast biology. He explores how inflammatory signals and cytokines influence these bone cells, contributing to diseases like periodontitis and bone metastasis. His second major interest lies in investigating the paracrine mechanisms in periodontal disease and identifying therapeutic targets for halting bone loss. Dr. Kim is also pioneering the cellular therapeutic application of dental stem cells for tissue regeneration, merging basic cell biology with clinical innovation. Additionally, he investigates the systemic implications of periodontal disease, linking oral health to broader systemic conditions. Through his research, he aims to develop more effective and targeted treatments for bone-related diseases, using a combination of molecular insights, stem cell therapy, and pharmacological interventions.

📚 Publications Top Notes:

📖 Elevated Expression of Cathepsin K in Periodontal Ligament Fibroblast by Inflammatory Cytokines Accelerates Osteoclastogenesis via Paracrine Mechanism in Periodontal Disease. (2021)
📖 Gastrin-Releasing Peptide (GRP) Stimulates Osteoclastogenesis in Periodontitis. (2021)
📖 Assessing the effects of cyclosporine A on osteoblastogenesis, osteoclastogenesis, and angiogenesis mediated by human periodontal ligament stem cells. (2020)
📖 Connective tissue growth factor (CTGF) regulates the fusion of osteoclast precursors by inhibiting Bcl6 in periodontitis. (2020)
📖 A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone. (2020)
📖 Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. (2019)
📖 Calcium-Phosphate Crystals Promote RANKL Expression via the Downregulation of DUSP1. (2019)
📖 Effects of Hispidulin on the Osteo/Odontogenic and Endothelial Differentiation of Dental Pulp Stem Cells. (2024)

🧾 Conclusion:

Dr. Hyung Joon Kim stands out as a highly qualified candidate for the Best Researcher Award. His extensive research in bone physiology, dental stem cells, and systemic disease mechanisms reflects both scientific rigor and practical application. With a proven track record of leadership, academic productivity, and impactful focus areas, he exemplifies the qualities of an innovative and dedicated researcher.

Chenlong YANG | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Prof. Chenlong YANG | Cancer Cell Biology | Best Researcher Award

Prof. Chenlong YANG, Peking University Third Hospital, China

Dr. Chenlong Yang, M.D., Ph.D., is an accomplished neurosurgeon and research associate professor at the Department of Neurosurgery, Peking University Third Hospital. With over 15 years of clinical and research experience, he specializes in neuro-oncology, spinal neurosurgery, and translational neuroscience. Dr. Yang earned his M.D. from Shandong University and his Ph.D. in Neurological Surgery from Capital Medical University. He has trained and worked in prestigious institutions including Beijing Tiantan Hospital and the State Key Laboratory of Vascular Homeostasis and Remodeling. He has contributed significantly to advancements in brain tumor diagnostics, neuroimmunology, and surgical innovations, with numerous high-impact publications. Recognized internationally, he frequently presents at top neurosurgical conferences such as EANS and the Japan-China Neurosurgery Alliance. His research bridges basic science and clinical neurosurgery, aiming to improve surgical precision and therapeutic outcomes. Dr. Yang is also known for his leadership in collaborative, multidisciplinary research teams.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. 📚 Robust Academic and Clinical Training

    • Earned an M.D. from Shandong University and a Ph.D. in Neurological Surgery from Capital Medical University.

    • Completed clinical training at Beijing Tiantan Hospital, a top-tier neurosurgical institution in China.

  2. 🔬 Multidisciplinary and Translational Research Excellence

    • His research spans neuro-oncology, neuroimmunology, spinal neurosurgery, and advanced neuroimaging.

    • Conducted preclinical work on Alzheimer’s disease models and neuroprotection, along with current research in immune checkpoint therapy and intraoperative imaging.

  3. 📈 High-Impact Publications

    • Over 20 peer-reviewed publications in journals such as Scientific Reports, J Exp Clin Cancer Res, Neurosurgical Review, and Biophysical Journal.

    • His research on chordomas, gliomas, and spinal tumors has significantly contributed to the field.

  4. 🌍 International Recognition

    • Speaker at major international conferences like EANS 2025 and KSNS 2024.

    • Previously awarded a scholarship by the Turkish Neurosurgical Society.

  5. 🤝 Leadership in Collaboration

    • Plays a key role at the Center for Precision Neurosurgery and Oncology and the State Key Laboratory of Vascular Homeostasis and Remodeling, fostering interdisciplinary collaborations across neurosurgery, imaging, and immunotherapy.

  6. 🎯 Focus on Precision and Innovation

    • Pioneering high-resolution MRI techniques, fluorescent intraoperative navigation, and predictive modeling for neurosurgical outcomes.

🔄 Areas for Improvement:

  1. 📊 Independent Research Lead

    • While he has several corresponding author papers, increasing his share of first-author or sole-PI grants would further elevate his research identity.

  2. 🌐 Global Collaborations

    • Though he has spoken at international conferences, expanding collaborative projects with leading global neuroscience centers could amplify impact.

  3. 💡 Technology Commercialization

    • Given his innovation in imaging and diagnostics, pursuing intellectual property rights or translational funding (e.g., for clinical tools or surgical systems) could be a valuable next step.

  4. 📄 Diversification of Research Outputs

    • A few review articles and meta-analyses would strengthen his role as a thought leader and field synthesizer.

📘 Education:

Dr. Yang pursued his foundational medical education at Shandong University, earning an M.D. in Clinical Medicine (2006–2011). This training provided a solid clinical base and early exposure to neurology and internal medicine. He then advanced to a doctoral program at Capital Medical University, Beijing (2011–2017), earning his Ph.D. in Neurological Surgery. During his Ph.D., he received specialized training in neurosurgical techniques and engaged in cutting-edge research, particularly focusing on neuro-oncology and degenerative neural diseases. As part of his early research career, he also worked at the Institute of Neurobiology, Shandong University, investigating neuroprotective agents and Alzheimer’s disease models. Dr. Yang’s academic journey is characterized by rigorous clinical training and scientific inquiry, equipping him with the knowledge and skills essential for bridging the gap between the lab bench and the operating room. His education laid a strong foundation for his future contributions to precision neurosurgery and translational neuroscience.

💼 Experience:

Dr. Yang has over a decade of diversified experience across top medical and research institutions. He currently serves as a Research Associate Professor and Attending Physician at the Department of Neurosurgery, Peking University Third Hospital (2020–present), where he leads several clinical and translational research projects. Prior to this, he completed a postdoctoral fellowship (2017–2020) in the Department of Orthopedics at the same hospital, emphasizing spinal and neuro-oncologic conditions. From 2011 to 2017, he worked as a resident in Neurosurgery at Beijing Tiantan Hospital, one of China’s premier neurosurgical centers, gaining extensive experience in surgical treatments and neurovascular procedures. His roles span clinical surgery, research coordination, and academic instruction. Additionally, he actively contributes to the Center for Precision Neurosurgery and Oncology and the State Key Laboratory of Vascular Homeostasis and Remodeling, leading initiatives to improve patient outcomes through interdisciplinary innovations in neurosurgical care.

🧠 Research Focus:

Dr. Chenlong Yang’s research integrates neurosurgery, oncology, immunology, and biomedical engineering. His primary focus lies in neuro-oncology, with a strong emphasis on chordoma biology, glioma immunotherapy, and molecular diagnostics. He explores immune checkpoint therapies, tumor microenvironment modulation, and the development of predictive models for neurosurgical complications such as postoperative delirium. Dr. Yang is also deeply involved in technological innovation in neurosurgery, investigating intraoperative fluorescence imaging, high-resolution MRI, and minimally invasive spinal techniques. His work on spatial learning, Alzheimer’s models, and neuroprotection during his early career continues to inform his translational research. He collaborates across disciplines, from molecular biologists to radiologists, aiming to build precision-guided therapeutic frameworks. His research is extensively published in journals like Scientific Reports, J Exp Clin Cancer Res, and Frontiers in Neurology. Through this work, Dr. Yang seeks to advance the standard of care in neurosurgical oncology and promote patient-specific interventions.

📚 Publication Top Notes:

  1. 🧬 SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas

  2. 🛡️ Cracking Chordoma’s Conundrum: Immune Checkpoints Provide a Potential Modality

  3. 🌱 From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms – a review

  4. 💡 Intraoperative fluorescence redefining neurosurgical precision

  5. 🧠 The evolution and integration of technology in spinal neurosurgery: A scoping review

  6. 👁️ Single-cell transcriptomic atlas of aging macaque ocular outflow tissues

  7. 🧮 Risk stratification and predictive modeling of postoperative delirium in chronic subdural hematoma

  8. 📶 Characteristic fingerprint spectrum of α-synuclein mutants on terahertz time-domain spectroscopy

  9. 🐒 Normative profile of retinal nerve fiber layer thickness in cynomolgus monkeys

  10. 🌀 Accurate diagnosis and treatment of sacral meningeal cysts using high-resolution MRI

  11. 🧪 Intraspinal hemangioblastomas: analysis of 92 cases in a single institution

🏁 Conclusion:

Dr. Chenlong Yang exemplifies the ideal profile of a cutting-edge clinician-scientist, merging neurosurgical precision with immunological insight and technological innovation. His commitment to patient-centered research, consistent academic output, and recognition on international platforms underscores his eligibility for the Best Researcher Award. With continued growth in independent leadership and global research impact, Dr. Yang is not only a deserving candidate now but is poised to become a prominent global figure in neurosurgical research in the years to come.

Nives Jonjić | Cancer Cell Biology | Women Researcher Award

Posted on by Cell Biologist

Prof. Dr. Nives Jonjić | Cancer Cell Biology | Women Researcher Award

Prof. Dr. Nives Jonjić | Department of Pathology and Citology, CHC Rijeka | Croatia

Prof. Nives Jonjić, MD, is a Full Professor Emeritus at the Department of General Pathology and Pathological Anatomy, Faculty of Medicine, University of Rijeka, Croatia. With a distinguished academic and clinical career spanning decades, Prof. Jonjić has made significant contributions to oncologic and molecular pathology. Her work focuses on understanding molecular markers in tumor progression and their diagnostic and prognostic relevance. As a prolific researcher and author, she has published extensively in high-impact international journals and collaborated with leading experts in pathology and oncology. Known for her diagnostic precision and dedication to academic mentorship, she has guided numerous medical students, residents, and doctoral candidates. Her legacy includes groundbreaking studies on biomarkers like Nectin-2 and Nectin-4 and rare pathologic entities. Prof. Jonjić’s leadership and scientific rigor make her a prominent figure in Croatian medical science and a respected name in international pathology circles.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Academic and Clinical Experience
    Prof. Nives Jonjić is a Full Professor Emeritus in pathology with decades of clinical, academic, and research experience, making her a veteran in her field.

  2. Strong Research Track Record

    • Multiple first and co-authored papers in peer-reviewed journals such as Current Issues in Molecular Biology, Pathology Research and Practice, and Clinical Pathology.

    • A clear focus on oncologic pathology, including biomarkers (e.g., Nectin-2 and Nectin-4), angiogenesis, lymphomas, and myelomas.

  3. Mentorship and Academic Leadership
    She has played a key role in mentoring junior scientists, guiding doctoral research, and shaping curriculum and teaching in pathology at the University of Rijeka.

  4. Work on Rare and Challenging Diagnoses
    Her research includes diagnostic dilemmas and rare malignancies, showing depth and clinical relevance, such as CD20-negative B-cell lymphomas and extranodal Hodgkin lymphomas.

  5. Contribution to Women in Science
    As a senior female figure in medicine, her position as a full professor and mentor has made her a role model in advancing women’s participation in scientific leadership roles.

📉 Areas for Improvement:

  1. Broader International Visibility
    While her research is of high quality, greater engagement in global collaborative projects, EU-funded consortia, or as a keynote speaker in international forums could enhance her visibility outside Croatia.

  2. Higher Citation Metrics and Impact Index
    Although several of her publications are impactful, a few are recent and not yet widely cited. Participation in meta-analyses or review articles might help amplify her citation footprint.

  3. Digital and Social Research Presence
    A more proactive presence on platforms like ResearchGate, ORCID, or Google Scholar and involvement in open-access science movements could increase accessibility to her work.

🎓 Education:

Prof. Nives Jonjić completed her Medical Degree (MD) at the Faculty of Medicine, University of Rijeka, where she also pursued her postgraduate education and specialization in pathology. Her academic excellence was evident early in her medical training, leading to her progression into research and teaching. She earned her doctoral degree (PhD) with a focus on tumor biology and pathology. Over the years, she attended various advanced courses and workshops in Europe related to histopathology, immunohistochemistry, and oncologic diagnostics. Her commitment to continuous learning kept her updated with evolving trends in cancer research and molecular pathology. Through rigorous training and international collaborations, she established herself as a scholar deeply engaged with both clinical and experimental pathology. Her educational path reflects a deep integration of medical knowledge, critical inquiry, and a lifelong dedication to academic excellence.

🧪 Professional Experience:

Prof. Nives Jonjić has over 35 years of experience in academic medicine and pathology. Beginning as a junior lecturer and advancing through roles of Associate Professor and Full Professor, she served at the Faculty of Medicine, University of Rijeka, where she also led the Department of General Pathology and Pathological Anatomy. Her clinical practice included diagnostic histopathology with subspecialty interests in hematopathology, soft tissue tumors, and gynecologic oncology. She played a key role in curriculum development, faculty mentorship, and postgraduate training. As an expert pathologist, she consulted on complex diagnostic cases nationally and internationally. Beyond clinical and teaching roles, she has been a principal investigator and co-investigator in multiple research projects and has evaluated numerous PhD theses. Her rich experience spans clinical excellence, research leadership, and educational mentorship, making her a pillar in Croatian medical academia.

🏆 Awards and Honors:

Prof. Nives Jonjić has received numerous awards and accolades throughout her career for her contributions to medical research, education, and clinical pathology. Among her honors are institutional recognition for excellence in teaching from the University of Rijeka, national awards for research contributions, and commendations from Croatian medical societies. She has also been invited to deliver keynote lectures at international conferences and served as a peer reviewer for esteemed pathology journals. Her election as Full Professor Emeritus reflects the high regard in which she is held by her peers and institution. Prof. Jonjić has been actively involved in academic boards and ethical committees and received acknowledgments for advancing women’s leadership in medicine. Her work continues to inspire future generations of medical researchers and clinicians, and her accolades affirm her dedication to science, education, and healthcare.

🔬 Research Focus:

Prof. Jonjić’s research primarily focuses on tumor pathology, with special emphasis on the expression and role of molecular biomarkers such as Nectin-2, Nectin-4, osteopontin, and NF-κB in cancer progression, diagnosis, and prognosis. Her studies span various malignancies including squamous cell carcinomas, glial tumors, lymphomas, and multiple myeloma. She is also engaged in investigating rare and diagnostically challenging pathological conditions, contributing to more accurate clinical-pathologic correlations. Her recent research has emphasized angiogenesis, immune profiling, and the tumor microenvironment. She employs advanced histopathological and immunohistochemical techniques to support translational applications in pathology. Through collaboration with multidisciplinary teams, her work bridges laboratory findings with clinical decision-making. Her research is widely cited, reflecting its importance in improving diagnostic accuracy and treatment stratification in oncology. Prof. Jonjić’s academic leadership and focus on innovative diagnostic markers make her a central figure in Croatian cancer research.

📚 Publications Top Notes:

  1. 🗣️ Laryngeal Squamous Cell Carcinoma Is Characterized by a Stronger Expression of Nectin-4 Compared to Nectin-2

  2. 🧠 The Prognostic Significance of Nectin-2 and Nectin-4 Expression in Glial Tumors

  3. 💉 Anti-angiogenic Effect of Bortezomib Treatment in Multiple Myeloma Associated with Lower NF-κB and OPN Expression

  4. 🔬 Primary Nodal Unclassifiable CD20 Negative Diffuse Large B-cell Lymphoma With Dual IgK and TCR Gene Rearrangement

  5. 🦴 Angiogenesis and Osteopontin Expression in Paraskeletal Myeloma With Plasmablastic Morphology

  6. 🧪 Diagnostic Challenge of Soft Tissue Extranodal Hodgkin Lymphoma in Core-Needle Biopsy

  7. 💊 Lichen Planus Pigmentosus-like Reaction to Pirfenidone in Idiopathic Pulmonary Fibrosis

  8. 🦷 Recurrent Adamantinoma With Fibrous Dysplasia-like Feature

  9. 💉 Adalimumab as a Risk Factor for Development of Melanocytic Lesions

  10. 🧬 Expression Profiles of Metallothionein-I/II and Megalin/LRP-2 in Uterine Cervical Lesions

🏁 Conclusion:

Prof. Nives Jonjić is a highly suitable candidate for the Research for Women Researcher Award. Her scholarly contributions in pathology, especially tumor diagnostics and molecular markers, are significant and clinically relevant. Her work is anchored in academic integrity and mentorship, fostering the next generation of medical scientists. While global visibility could be enhanced, her regional impact, sustained productivity, and role as a senior academic make her a strong and deserving nominee.

 

Tamara Braut | Cancer Cell Biology | Innovative Research Award

Posted on by Cell Biologist

Prof. Dr. Tamara Braut | Cancer Cell Biology | Innovative Research Award

Prof. Dr. Tamara Braut | Faculty of Medicine, University of Rijeka/ENT Clinic, Clinical hospital centre Rijeka | Croatia

Professor Tamara Braut, MD, is a renowned Croatian otorhinolaryngologist and Full Professor at the Faculty of Medicine, University of Rijeka. She serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery. Her clinical expertise and academic leadership have significantly contributed to advancements in the diagnosis and treatment of head and neck cancers, particularly laryngeal carcinoma. With over two decades of experience, Dr. Braut is widely recognized for her work in molecular oncology, HPV-associated head and neck tumors, and translational medicine. A frequent collaborator on interdisciplinary and international projects, she is committed to personalized medicine and innovative approaches in clinical research. Her impressive portfolio of peer-reviewed publications, including case studies, multicenter analyses, and biomarker-based diagnostics, highlights her dedication to evidence-based practice and academic excellence. Professor Braut’s academic leadership and clinical insight place her among the top contributors in her specialty within Croatia and internationally.

Publication Profile:

Google Scholar

Strengths For Award:

  • Pioneering work in head and neck oncology and molecular diagnostics

  • Significant publication record in high-impact journals

  • Collaborative multicenter research and precision medicine orientation

  • Demonstrated leadership in academic and clinical settings

  • Integration of clinical insights with research innovation

Areas for Improvement:

  • Broaden research beyond oncology to explore ENT-related AI/technology

  • Increase international collaborations and visibility at global conferences

  • Expand into clinical trials for therapeutics in HPV+ cancers

🎓 Education: 

Prof. Tamara Braut received her Doctor of Medicine (MD) degree from the University of Rijeka, Croatia, where she also completed her specialization in Otorhinolaryngology. Her academic path was distinguished by an early interest in oncology, molecular pathology, and surgical innovation. She pursued postgraduate training and research with a focus on laryngeal and head and neck cancers. Throughout her education, she was actively involved in academic research, participating in numerous national and international conferences, which sharpened her analytical and investigative skills. She later obtained her PhD with a focus on molecular markers in squamous cell carcinoma. Over the years, she has pursued continuous professional development in precision medicine, oncology biomarkers, and evidence-based surgical practices. Her academic and clinical training has made her a highly competent physician-scientist, well-versed in both patient care and experimental research.

🧑‍🔬 Experience:

Prof. Tamara Braut has over two decades of experience in clinical and academic medicine. She currently serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery at the Faculty of Medicine, University of Rijeka. Her career spans clinical work, academic leadership, surgical practice, and scientific research. She has treated complex cases involving laryngeal and head-neck cancers and has led multidisciplinary teams in oncology care. As an educator, she has supervised medical students, residents, and PhD candidates, many of whom now hold academic and clinical positions. Dr. Braut is a prolific researcher, contributing to over 40 peer-reviewed articles, case studies, and reviews. Her leadership in multicenter studies and her role as a principal investigator in several clinical research projects highlight her competence in collaborative and innovative medical research.

🔬 Research Focus:

Prof. Braut’s research focus lies at the intersection of head and neck oncology, molecular diagnostics, and personalized medicine. She has a keen interest in biomarker discovery, especially in HPV-positive head and neck squamous cell carcinomas, and the role of EGFR signaling pathways in cancer progression. Her work includes translational research linking clinical findings with molecular data to improve prognosis, diagnosis, and treatment strategies. She has also explored the impact of hormonal therapies, gene expression markers like Ki-67 and IMP3, and novel imaging and diagnostic tools. In recent years, she has expanded her interest to gastroesophageal reflux disease and its implications in ENT disorders. Her contributions reflect a consistent commitment to advancing precision medicine, long-term patient follow-up, and multimodal treatment outcomes. She continues to integrate research into clinical practice, thereby fostering innovation and improved patient care in the otorhinolaryngology field.

📚 Publications List Top Notes:

  1. 🧬 Laryngeal SCC shows stronger Nectin-4 vs Nectin-2 expression – CIMB (2025)

  2. 🥗 GERD Management: From PPIs to Diet & Lifestyle – Gastrointest. Disord. (2025)

  3. 🔍 Advances in HPV-Positive Head & Neck Cancer Diagnostics – Biomolecules (2024)

  4. 🧪 Biomarkers in HPV+ Head and Neck SCC: Precision Medicine – Diagnostics (2024)

  5. 💉 Testosterone Therapy in Advanced Head & Neck SCC – Crit. Rev. Oncol. Hematol. (2023)

  6. 🏥 Long-Term Care in Laryngeal Cancer: Multicenter Analysis – J Pers. Med (2023)

  7. 📊 5-Year Clinical Course in Laryngeal Tumors – Acta Clin. Croatica (2022)

  8. 🧫 Renal Cell Carcinoma Metastasis to Larynx: Rare Case – Medicina Flum (2021)

  9. 🧠 Posttraumatic Vernet Syndrome without Fracture: Case Study – Medicine (2021)

  10. ⚛️ Nuclear EGFR Expression = Poor Survival in Laryngeal Ca – AIMM (2021)

Conclusion:

Prof. Tamara Braut is highly deserving of the Innovative Research Award. Her work showcases originality, clinical relevance, and scientific depth. With a robust academic and clinical foundation, she continues to push the boundaries in ENT oncology and diagnostics.

 

Gökçe Karaotmarlı Güven | Cancer Cell Biology | Best Research Article Award

Posted on by Cell Biologist

Mrs. Gökçe Karaotmarlı Güven | Cancer Cell Biology | Best Research Article Award

Mrs. Gökçe Karaotmarlı Güven | Biruni University, Faculty of Pharmacy | Turkey

Gökçe Karaotmarlı Güven, born on July 22, 1996, is a dynamic and passionate Research Assistant with a strong academic foundation in pharmaceutical sciences. She earned her Bachelor’s degree from Biruni University, Faculty of Pharmacy in 2020, and is currently pursuing her Ph.D. in Pharmaceutical Technology at Health Sciences University, where she is deeply involved in cutting-edge nanomedicine research. Her expertise lies in carbon quantum dots, drug delivery systems, and bio-nanotechnology. Gökçe has collaborated on innovative research projects and has contributed significantly to the scientific community through high-impact publications and patent filings. Her interdisciplinary research combines pharmaceutical technology, nanoscience, and biotechnology, aiming to advance targeted drug delivery for diseases like cancer. She is recognized for her analytical mindset, scientific curiosity, and collaborative spirit, which fuel her aspiration to become a leading figure in pharmaceutical nanotechnology. Gökçe continues to explore novel therapeutic technologies to address some of the most pressing challenges in modern medicine.

orcid

✅ Strengths for the Award:

  1. Innovative Research:
    Gökçe has demonstrated a clear focus on high-impact, novel research—especially with her work on boron-doped carbon quantum dots for targeted drug delivery and cancer therapy. Her work represents a pioneering intersection of nanotechnology and pharmaceutical sciences.

  2. High-Quality Publications:
    She has published in internationally respected journals such as Pharmaceuticals, Applied Sciences, and Journal of Research in Pharmacy. The topics she covers—quantum drug development, phytochemical-based wound therapies, and ocular drug delivery—are timely and significant to global health.

  3. Patent Contributions:
    With three patent applications (2024–2025), her research is not only academic but also translational and innovation-driven, showing real-world applicability—a vital criterion for research excellence awards.

  4. Collaborative and Interdisciplinary Work:
    Gökçe has worked with both national and international teams, indicating strong teamwork, adaptability, and leadership in multidisciplinary settings.

🔄 Areas for Improvement:

  1. Broader Publication Indexing:
    Although her work is high quality, more publications in top-tier Q1 journals indexed by PubMed/Scopus/Web of Science would further validate her research’s global impact and improve her visibility.

  2. Post-Doctoral Research Exposure:
    Expanding her research experience internationally through postdoctoral fellowships or collaborations abroad could enhance the depth of her academic profile and increase her competitiveness for global-level research awards.

  3. Greater Conference Participation:
    Active presentation in international conferences, symposiums, or research summits would broaden her academic reach and help disseminate her innovations to a larger audience.

🎓 Education:

Gökçe Karaotmarlı Güven’s educational background reflects her commitment to pharmaceutical sciences and innovation. She obtained her Bachelor’s degree from the Faculty of Pharmacy at Biruni University in 2020, where she developed a solid understanding of pharmaceutical chemistry and drug formulation. Currently, she is pursuing a Ph.D. in Pharmaceutical Technology at the Health Sciences University, Hamidiye Faculty of Pharmacy. Her doctoral research is focused on the synthesis, biodistribution, and pharmacokinetics of boron-doped carbon quantum dots—highly advanced nanomaterials with potential applications in drug delivery and cancer therapy. Under the mentorship of Prof. Dr. Neslihan Üstündağ Okur and co-advisor Prof. Dr. İsmail Tuncer Değim, she is conducting high-level research that blends nanotechnology with targeted therapeutic systems. Her academic training is complemented by active involvement in laboratory-based innovation and scholarly writing, making her well-prepared for an impactful career in both academia and the pharmaceutical industry.

💼 Experience:

Gökçe Karaotmarlı Güven is currently working as a Research Assistant at Health Sciences University, where she contributes to numerous multidisciplinary projects in the field of pharmaceutical nanotechnology. Her professional journey began with laboratory internships and academic projects during her undergraduate years, focusing on drug formulation and ocular drug delivery systems. During her Ph.D., she has played a pivotal role in designing and characterizing nanocarriers for targeted drug delivery, particularly in cancer treatment and wound healing. Her hands-on experience includes formulation science, analytical instrumentation, preclinical biodistribution studies, and in vitro pharmacokinetics. Gökçe has been involved in patentable inventions and has co-authored multiple high-impact journal articles in international journals. Her collaborations span across Turkish and international institutions, showcasing her ability to work in team-based research environments. Her strengths lie in research design, scientific communication, and a deep understanding of advanced drug delivery systems, making her an asset to any pharmaceutical research team.

🔬 Research Focus:

Gökçe Karaotmarlı Güven’s research centers on the intersection of nanotechnology and pharmaceutical sciences, particularly in the development of carbon quantum dots (CQDs) for targeted drug delivery. Her doctoral thesis involves the preparation, biodistribution, and pharmacokinetic evaluation of boron-doped carbon quantum dots and composite carbon quantum dots, aimed at enhancing drug delivery efficiency in cancer treatment. Her interests extend to quantum drug technologies, ocular drug delivery systems, and hydrogel formulations containing bioactive molecules. Through her collaborative research, she explores the role of nanoformulations in wound healing, antimicrobial applications, and personalized medicine. Gökçe is particularly passionate about applying nanotechnology to solve real-world therapeutic challenges, especially in cancer and ophthalmic care. Her work is informed by a multidisciplinary approach, blending pharmaceutical chemistry, nanoscience, and biotechnology. Her research is innovative, patentable, and addresses unmet needs in the current pharmaceutical landscape, positioning her as a rising scholar in next-generation drug delivery systems.

📚 Publications Top Notes:

  1. 🧬 Quantum Drugs (Q-Drugs): A New Discovery and Taboo Breaking Approach; Producing Carbon Quantum Dots from Drug Molecules – Pharmaceuticals, 2025-05-22

  2. 🌿 Nanoformulations Loaded with Phytochemicals for Combating Wound Infections and Promoting Wound Healing – Applied Sciences, 2025-05-12

  3. 👁️ In situ gels loaded with naringin as ocular drug delivery carriers; development and preliminary characterization – Journal of Research in Pharmacy, 2024

  4. 💧 Preparation and characterization of carbopol based hydrogels containing dexpanthenol – Ankara Universitesi Eczacilik Fakultesi Dergisi, 2023-06-12

📝 Conclusion:

Gökçe Karaotmarlı Güven stands out as a highly promising young researcher whose work is innovative, scientifically sound, and application-focused. Her contributions to the development of novel drug delivery systems, particularly through carbon quantum dots and nanomedicine strategies, mark her as a deserving candidate for the Best Research Article Award.

Her work aligns with the values such awards seek to recognize: originality, relevance, translational impact, and collaborative strength. With continued growth in international exposure and expanded publication reach, she will not only be a worthy recipient now but also an influential leader in pharmaceutical nanotechnology in the future.

Marija Gjorgoska | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Mrs. Marija Gjorgoska | Cancer Cell Biology | Best Researcher Award

Mrs. Marija Gjorgoska | Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana | Slovenia

Marija Gjorgoska is a dedicated biomedical researcher and teaching assistant at the Faculty of Medicine, University of Ljubljana, Slovenia. With a strong background in biochemistry, molecular biology, and bioinformatics, she has contributed significantly to cancer research, focusing on steroid hormone signaling in gynecological cancers. Her scientific work combines analytical expertise in LC-MS/MS with a solid foundation in molecular biology and statistical analysis using R programming. Marija is passionate about advancing clinical diagnostics and cancer treatment through high-precision biomolecular profiling. Her academic journey reflects international exposure through internships in the UK and Macedonia. She is known for her collaborative spirit and commitment to scientific rigor, which has led to multiple high-impact publications. Marija continues to mentor students and contribute to the academic community through her teaching role, making her a rising figure in molecular oncology research.

publication profile:

scopus

Strengths:

  1. High Research Productivity 📈
    Marija Gjorgoska has authored or co-authored 10 peer-reviewed publications in high-impact journals such as Progress in Lipid Research (IF 14.0), Trends in Endocrinology and Metabolism (IF 11.4), and Cancers. Her work shows consistent scientific output, often with first or shared first authorship.

  2. Cutting-Edge Technical Expertise 🔬
    She demonstrates advanced proficiency in LC-MS/MS method development, multi-steroid profiling, and bioinformatics (R programming). This makes her an expert in translational hormone research and biomarker discovery.

  3. Clinical Relevance and Innovation ⚕️
    Her research addresses urgent clinical challenges like endometrial cancer diagnosis and ovarian cancer drug resistance, applying modern analytical techniques combined with machine learning, which positions her at the forefront of personalized medicine.

  4. Recognition and Collaboration 🤝
    She has been awarded prestigious grants (e.g., Society of Endocrinology, UK), collaborated internationally (UK, Macedonia), and contributes to academia as a teaching assistant—all signs of an emerging research leader.

  5. Interdisciplinary Impact 🌐
    Marija effectively integrates molecular biology, biochemistry, analytical chemistry, and computational biology—indicative of her versatility and broad scientific impact.

Areas for Improvement:

  1. Independent Research Leadership
    While she has made substantial contributions as a junior and co-investigator, future work could benefit from establishing herself as a principal investigator or project leader, including securing her own research funding.

  2. Diversification of Research Themes
    Her focus has been predominantly on hormone-related cancers. Expanding into other disease models or mechanisms could broaden her impact and create new collaborative opportunities.

  3. Public Engagement and Outreach
    Enhancing her visibility through conference presentations, science communication, or community health initiatives would further solidify her standing as a leader and advocate for biomedical research.

Education :

Marija Gjorgoska is currently enrolled in a doctoral program in Biomedicine, specializing in Biochemistry and Molecular Biology at the University of Ljubljana. Her academic foundation includes a Master’s degree in Molecular Biology (2018–2021) from the same university, completed with an outstanding GPA of 9.52/10. She also gained international experience through a short-term internship at the University of Birmingham, UK, in 2023, focusing on advanced LC-MS/MS techniques for clinical sample analysis. Earlier in her academic career, she completed a long-term internship at the Research Center for Genetic Engineering and Biotechnology in Skopje, Macedonia (2017), where she worked on genetic diagnostics involving haemoglobinopathies, HPV, HBV, and HCV detection. Her education has consistently emphasized both theoretical knowledge and hands-on laboratory skills, particularly in analytical chemistry, molecular biology, and bioinformatics, all of which shape her current research endeavors in cancer diagnostics and hormonal regulation.

Experience:

Marija Gjorgoska has been actively engaged in research since 2020 as a Research Assistant at the Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana. Her core responsibilities include developing and validating LC-MS/MS analytical methods, conducting proteomic and genetic analyses of cancer tissues, and performing bioinformatic evaluations using R programming. In October 2024, she also began serving as a Teaching Assistant for the course “Principles of Biochemistry,” demonstrating her commitment to education and mentorship. Marija’s prior internships have equipped her with valuable skills in prenatal and infectious disease diagnostics. Her research contributions span experimental planning, scientific writing, and instrument maintenance, establishing her as a versatile scientist. Her collaborative projects with international researchers and clinicians further underline her strength in translational biomedical research. This combination of teaching, laboratory, and analytical expertise supports her growing influence in molecular oncology.

Awards and Honors:

Marija Gjorgoska has been recognized for both academic and research excellence. In 2023, she was awarded the Practical Skills Grant by the Society of Endocrinology, UK, enabling her to undergo advanced training in LC-MS/MS at the University of Birmingham. Earlier, in 2021, she received the Krka Recognition with Special Praise for her Master’s thesis, highlighting her early promise as a researcher in molecular biology. Her scientific publications have appeared in top-tier journals such as Progress in Lipid Research and Trends in Endocrinology and Metabolism, some with impact factors exceeding 14.0. Notably, she earned shared first co-authorship in Methods in Enzymology for her work on enzymatic assay development. These accolades reflect her technical excellence, originality, and scientific contributions in the field of steroid metabolism and gynecological cancers. Marija’s achievements distinguish her as a young researcher with significant impact and high potential for further contributions to science and medicine.

Research Focus :

Marija Gjorgoska’s research focuses on the role of steroid hormones in the development and progression of gynecological cancers, particularly endometrial and ovarian cancers. Her work integrates analytical chemistry (LC-MS/MS), bioinformatics, and molecular biology to uncover diagnostic and prognostic biomarkers. She has developed multi-steroid profiling techniques to differentiate between normal and cancerous tissues, aiding early diagnosis. Marija’s studies also address the pre-receptor regulation of androgenic and estrogenic hormones, exploring their signaling dynamics at the tissue level. Using tools such as Mendelian randomization, she investigates genetic influences on hormone-related disease risk. Her interdisciplinary approach combines advanced mass spectrometry, statistical modeling, and clinical collaboration to translate bench science into meaningful medical applications. Through high-impact publications, she contributes to understanding hormone metabolism in cancer microenvironments, with the goal of informing targeted therapies and overcoming drug resistance. Her work is critical for advancing personalized medicine in hormone-driven malignancies.

Publications Top Notes:

  1. 📘 From fallopian tube epithelium to high-grade serous ovarian cancer: A single-cell resolution review of sex steroid hormone signaling – Progress in Lipid Research, 2024

  2. 📘 Integration of androgen hormones in endometrial cancer biology – Trends in Endocrinology and Metabolism, 2022

  3. 📘 Steroid sulfatase and sulfotransferases in gynecological cancers: current status and perspectives – Essays in Biochemistry, 2024

  4. 📘 Estrogens and the Schrödinger’s cat in the ovarian tumor microenvironment – Cancers, 2021

  5. 📘 Multi-Steroid Profiling and Machine Learning Reveal Androgens as Biomarkers for Endometrial Cancer – Cancers, 2025

  6. 📘 Simultaneous measurement of 17 endogenous steroid hormones by LC-MS/MS – J. of Steroid Biochemistry and Molecular Biology, 2024

  7. 📘 11-oxyandrogens in normal vs. cancerous endometrium – Frontiers in Endocrinology, 2024

  8. 📘 Targeting estrogen metabolism to overcome platinum resistance in ovarian cancer – Biomedicine & Pharmacotherapy, 2024

  9. 📘 Effect of androgens on risk of endometriosis sub-phenotypes and ovarian neoplasms – J. of Steroid Biochemistry and Molecular Biology, 2024

  10. 📘 Enzymatic assays for 17β-HSD types 1 and 2 using mass spectrometry – Methods in Enzymology, 2023

Conclusion:

Marija Gjorgoska is a highly promising early-career researcher with a strong and growing international publication record, deep technical expertise in analytical biochemistry, and a clear focus on clinically relevant research. Her integration of hormonal pathway analysis with state-of-the-art analytical methods has already contributed valuable insights to the field of gynecological oncology. She has the academic rigor, curiosity, and collaborative drive essential for impactful science.

In my opinion, she is a highly suitable candidate for the Best Researcher Award. Continued mentorship and support toward independent research leadership will elevate her even further in the years to come.